Zai Lab Executive and Leadership Team

Junwei Zhang, the Chief of Staff To the Chief Executive Officer. Head of Commercial Strategy, NPP, and Operation Excellence at Zai Lab, architects the strategic framework for commercializing new pharmaceutical products. Overseeing operational excellence initiatives, the Chief of Staff To the Chief Executive Officer. Head of Commercial Strategy, NPP, and Operation Excellence ensures that internal processes align with the company's aggressive growth targets. This leadership role involves coordinating executive communications and driving the execution of commercial strategies across diverse regional markets. By streamlining organizational workflows, Junwei Zhang enhances the efficiency of the commercial team. The Chief of Staff To the Chief Executive Officer. Head of Commercial Strategy, NPP, and Operation Excellence facilitates collaboration between departments to ensure seamless product launches and market penetration. Through the application of data-driven insights, the Chief of Staff To the Chief Executive Officer. Head of Commercial Strategy, NPP, and Operation Excellence optimizes the company's go-to-market approach. Ultimately, Zhang drives the commercial success of the organization by maintaining operational rigor and strategic focus.

Xiaoxi Wang, the Deputy Chief Financial Officer at Zai Lab, manages the fiscal health and capital allocation strategies of the organization. Overseeing financial reporting and investor relations, the Deputy Chief Financial Officer ensures transparency and compliance with international regulatory standards. This leadership role involves analyzing market trends to support the company's expansion into new therapeutic markets. By directing budgetary planning and risk management, Xiaoxi Wang provides the necessary financial stability to sustain long-term drug development projects. The Deputy Chief Financial Officer collaborates with the executive team to evaluate potential partnerships and investment opportunities that enhance the company's market presence. Through the optimization of capital structures, the Deputy Chief Financial Officer supports the scaling of operations across global markets. Ultimately, Wang strengthens the financial foundation of the company, ensuring that resources remain focused on the core mission of delivering life-saving treatments to patients suffering from complex autoimmune and oncological diseases.

James Yan, the Chief Operating Officer, Research & Development at Zai Lab, directs the end-to-end drug discovery pipeline. Overseeing complex laboratory operations, the Chief Operating Officer, Research & Development ensures that scientific breakthroughs translate into viable clinical candidates. This leadership role involves managing cross-functional teams across the Asia-Pacific region to accelerate the development of oncology and autoimmune treatments. By optimizing resource allocation within the R&D department, James Yan maintains high standards of scientific integrity and operational efficiency. The Chief Operating Officer, Research & Development coordinates closely with the Board to align research milestones with long-term corporate growth objectives. Through the implementation of advanced biotechnology platforms, the Chief Operating Officer, Research & Development drives the expansion of the company's therapeutic portfolio. Ultimately, Yan secures the competitive position of the organization within the global bio-pharmaceutical landscape by fostering innovation and maintaining rigorous quality control protocols throughout the entire discovery process.

Harald Reinhart, the Chief Medical Officer at Zai Lab, leads the clinical development and medical affairs strategy for the company's oncology and autoimmune pipeline. Overseeing global clinical trials, the Chief Medical Officer ensures that all research activities adhere to the highest ethical and scientific standards. This leadership role involves engaging with regulatory bodies to facilitate the approval of innovative therapies. By directing the medical strategy, Harald Reinhart ensures that clinical data effectively supports the therapeutic value of the company's drug candidates. The Chief Medical Officer collaborates with the research team to identify unmet medical needs and prioritize development efforts accordingly. Through the management of international clinical networks, the Chief Medical Officer expands the reach of the company's medical initiatives. Ultimately, Reinhart drives the clinical success of the organization by ensuring that patient safety and scientific efficacy remain the primary focus of all medical operations and development activities.